LILA PECKHAM-WICHMAN: Open Payments
NPI 1366409427 · LENEXA, KS. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$370 in 19 payments from 8 companies in 2025. Trend: 2023 $91 · 2024 $360 · 2025 $370
Food & beverage: $370
| Company | Payments | Amount |
|---|---|---|
| Janssen Pharmaceuticals, Inc | 3 | $65 |
| Teva Pharmaceuticals USA, Inc. | 3 | $60 |
| Alkermes, Inc. | 3 | $59 |
| ABBVIE INC. | 3 | $57 |
| Otsuka America Pharmaceutical, Inc. | 3 | $57 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 2 | $39 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $19 |
| Vanda Pharmaceuticals Inc. | 1 | $14 |
Products named: INVEGA SUSTENNA, ARISTADA, VRAYLAR, REXULTI, UZEDY, CAPLYTA, TRINTELLIX, AUSTEDO XR.
Industry payments across KS — which companies pay providers there.
